The primary objective of this study is to evaluate the effect of Obeticholic Acid treatment compared to placebo on liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.
Contact site for start date.
Please contact ClinicalResearch@sutterhealth.org about Study Regenerate.
View study details on ClinicalTrials.gov
Subjects 18 years of age and older with histologic evidence of NASH following a liver biopsy obtained no more than 6 months before Day 1 and histologic evidence of fibrosis stage 1, stage 2 or stage 3.
June 01, 2018